Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Toxicological Effects
  • Genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names

North America

USA: Bromday, Bromfenac sodium, Xibrom (d).

Latin America

Argentina: Natax.


Japan: Bronuck.

Drug combinations


Bromfenac Sodium: C~15~H~11~BrNNaO~3~ 1½H~2~O. Mw: 383.17. (1) Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)-, monosodium salt, sesquihydrate; (2) Sodium [2-amino-3-(p-bromobenzoyl)phenyl]acetate sesquihydrate. CAS-120638-55-3; CAS-91714-94-2 (bromfenac)(1986).

Pharmacologic Category

EENT Preparations; Nonsteroidal Anti-inflammatory Agents. (ATC-Code: S01BC11).

Mechanism of action

Inhibits the synthesis of prostaglandins in body tissues by inhibiting cyclooxygenase (COX), including both COX-1/PTGS1 and COX-2/PTGS2 isoenzymes. By reducing ocular production of prostaglandins, NSAIDs can inhibit ocular inflammation and other reactions mediated primarily or secondarily by prostaglandins.

Therapeutic use

Management of postoperative ocular inflammation and pain.

Pregnancy and lactiation implications

Exposure to nonsteroidal anti-inflammatory drugs late in pregnancy may lead to premature closure of the ductus arteriosus and may inhibit uterine contractions. Use with caution during pregnancy or lactation.

Unlabeled use


Known hypersensitivity to bromfenac sodium or any ingredient in the formulation.

Warnings and precautions

Use with caution in previous sensitivity to acetylsalicylic acid and phenylacetic acid derivatives, including patients who experience asthma, bronchospasm, rhinitis, or urticaria following NSAID or aspirin. Formulation contains sodium sulfite, which may cause allergic-type reactions (including anaphylaxis and life-threatening or less severe asthmatic episodes) in certain susceptible individuals. May cause keratitis (risk of severe corneal adverse reactions). Diabetes mellitus or rheumatoid arthritis enhance risk of corneal adverse events. Use with caution in complicated ocular surgeries, corneal denervation, corneal epithelial defects, ocular surface disease, or repeat ocular surgeries within a short timeframe (risk of corneal adverse events). Use for more than 1 day prior to surgery or for 14 days beyond surgery may increase risk and severity of corneal adverse events. May slow or delay wound healing. May inhibit platelet aggregation and prolong bleeding time (caution in patients with underlying bleeding tendencies or in those receiving drugs known to prolong bleeding time). Patients using ophthalmic drops should not wear soft contact lenses.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart